Cranberry (Vaccinium macrocarpon)
Cranberry (Vaccinium macrocarpon) is the small red berry of a North American evergreen shrub. As a food supplement it is used primarily for urinary-tract-health support, by way of the proanthocyanidin (PAC) family — specifically A-type PACs that block uropathogenic Escherichia coli from adhering to urinary epithelium. The 2024 Cochrane review concluded cranberry products reduce the risk of symptomatic culture-verified UTIs in women with recurrent infections. There are no UK-authorised health claims for cranberry; marketing must remain descriptive.
Camden Medicals editorial · Last reviewed 2 May 2026 · Next review May 2027
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Botanical
- Typical daily dose
- Trial-grade dose: ≥36 mg PACs/day (BL-DMAC method). One concentrated extract tablet typically delivers cranberry equivalent of 5,000–7,500 mg whole fruit and may declare 36–72 mg PACs. Lower-strength capsules and juice products may need multiple servings to reach the trial dose.
- Top use evidence
- Moderate
On this page
What it is
Cranberry is the small red berry of Vaccinium macrocarpon (American cranberry — the species used in supplements and most juice). It is a member of the Ericaceae family, alongside blueberries and bilberries. The fruit contains organic acids (citric, malic, quinic, benzoic), simple sugars, vitamin C at modest levels, and a diverse polyphenol fraction including anthocyanins (cyanidin and peonidin glycosides, the red pigments) and proanthocyanidins (PACs).
The PAC fraction is what matters for urinary-tract use. PACs are classified as A-type or B-type by the chemistry of their inter-flavanoid linkage. Cranberry is unusual among edible plants in being rich in A-type PACs; most fruits and the cocoa supply chain are B-type-dominated. A-type PACs are the fraction with documented anti-adhesion activity against uropathogenic E. coli in laboratory and human urinary models.
Cranberry is sold as juice (sweetened or unsweetened concentrate), freeze-dried whole-fruit powder, encapsulated extract, and standardised tablets. Camden's encyclopaedia look-for bar is PAC content declared per serving in milligrams (not just "cranberry equivalent") — the trial-grade dose anchor is ≥36 mg PACs/day, measured by the BL-DMAC standardised assay.
At a glance
- Red berry of Vaccinium macrocarpon. UTI-prevention rationale rests on A-type proanthocyanidins (PACs) blocking E. coli adhesion.
- No UK-authorised health claim. PDP must stay descriptive.
- The 2024 Cochrane (Williams) review of 50 trials concluded cranberry products reduce the risk of symptomatic UTI in women with recurrent infections, in children, and in some other groups. Effect not consistent across all populations.
- Trial dose anchor is ≥36 mg PACs/day. Cranberry milligrams alone are uninformative without PAC content disclosure.
- Not a treatment for acute UTI — fever, pain, blood in urine, or pyelonephritis symptoms need NHS care.
What people use it for
Women with recurrent uncomplicated UTIs (≥3 episodes/year or ≥2 in 6 months)
The 2024 Cochrane review (Williams G, CD001321) concluded cranberry products reduce the risk of symptomatic culture-verified UTIs in women with recurrent infections. Daily cranberry supplementation delivering ≥36 mg PACs is the trial-grade dose. NICE CKS for recurrent UTI does not yet list cranberry as first-line prophylaxis but acknowledges the evidence trajectory. [3]
Some evidenceModerateChildren with recurrent UTIs (in addition to clinical care)
The 2024 Cochrane review pooled paediatric trials and reported a meaningful reduction in symptomatic UTIs in children. Use in children should be a GP / paediatrician decision rather than self-treatment. [3]
Some evidenceModerateAdults during or after antibiotic UTI courses, or before / after urological procedures
Mixed but generally supportive evidence. Discuss with your prescriber if you have had multiple antibiotic courses — there are now NICE prescribed-prophylaxis pathways too. [2]
Some evidenceLimitedAnyone with red-flag UTI symptoms (fever, flank pain, blood, vomiting, pregnancy, suspected pyelonephritis)
Cranberry is not a treatment for acute UTI. See a clinician urgently — these symptoms need antibiotic care or hospital assessment. [1]
Popular, not provenInsufficient
How it works
Most uncomplicated UTIs in women are caused by uropathogenic Escherichia coli (UPEC), which adhere to bladder urothelial cells via type-1 (mannose-sensitive) and P-type (mannose-resistant) pili. Cranberry A-type PACs interfere with P-type FimH-related adhesion in laboratory models — bacteria appear to lose grip on the urothelium and are flushed out in urine. Cranberry PACs accumulate in urine after ingestion, where the anti-adhesion effect occurs. The mechanism is physical / receptor-blocking, not antibacterial; cranberry does not kill bacteria.
Common myths
Myth"Cranberry juice cures UTIs."
RealityIt does not. The evidence is for prevention of recurrent UTIs. An acute UTI with fever, pain, or blood in urine needs NHS antibiotic care. Sweetened cranberry juice cocktails also deliver substantial sugar — a daily PAC-standardised supplement is a different exposure. [1]
Myth"All cranberry products work the same."
RealityThey do not. PAC content varies enormously. Two products both labelled "5040 mg cranberry equivalent" can deliver entirely different PAC content depending on extraction and the BL-DMAC assay result. The trial-grade dose anchor is ≥36 mg PACs/day — without PAC content on the label, you do not know what you are taking.
Myth"Cranberry kills bladder bacteria."
RealityIt is not antibacterial. The mechanism is anti-adhesion: PACs prevent E. coli from sticking to the bladder wall, so the bacteria are flushed out rather than killed.
Common online questions
Synthesised from the questions UK shoppers most often ask online about Cranberry (Vaccinium macrocarpon). Each answer is editorial and links to its evidence in the Sources list below.
Cranberry juice or cranberry capsule — which is better?
For UTI-prevention use, capsule supplements with declared PAC content are more reliable than juice — juice PAC content varies with brand, dilution, and added sugar. The trial-grade anchor is ≥36 mg PACs/day, achievable through a standardised extract. Sweetened cranberry juice cocktails are a different product with much lower PAC density per serving. [3]
Can I take cranberry alongside D-mannose?
Yes — combinations are common. The two work via overlapping but not identical anti-adhesion pathways and are not contraindicated together. Some commercial UTI-prevention products combine both. As always, talk to your pharmacist if you take prescribed medication.
Will cranberry interact with my warfarin?
Older case reports raised concern about cranberry juice increasing INR in warfarin patients; subsequent prospective studies have not consistently replicated this. UK anticoagulation guidance is to be cautious — disclose use to your anticoagulation team, especially if starting or stopping cranberry abruptly.
Can I take cranberry in pregnancy?
UTI in pregnancy needs prompt clinical care — pyelonephritis in pregnancy is serious. The Cochrane review did not show consistent benefit in pregnant women. Talk to your midwife before starting cranberry supplementation.
How long should I stay on cranberry?
Most prevention trials run 3 to 6 months. If you remain symptom-free, you may continue or stop and resume on recurrence. If symptoms persist or worsen on cranberry, discuss prescribed prophylaxis options with your GP.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Recurrent urinary tract infection prevention (women + children)
ModerateEvidencemoderateCochrane CD001321.pub6 (Williams 2023, updated 2024) pooled 50 trials of cranberry products. The review concluded cranberry-derived products reduce the risk of symptomatic culture-verified UTIs in women with recurrent infections, in children, and in those susceptible to UTIs after urological procedures or radiotherapy. Effect was not seen consistently in pregnant women, the elderly in residential care, or long-term-catheterised adults. The 2012 review had been equivocal; the 2023/2024 update reflects newer trials and better PAC standardisation. [3]
Acute UTI treatment
InsufficientEvidenceinsufficientCranberry is not for acute symptomatic UTI. NHS / NICE pathway is short-course antibiotic therapy via GP, NHS 111, or Pharmacy First (UTI in women 16-64). [2]
Catheter-associated UTI prevention
LimitedEvidencelimitedCochrane analysis: insufficient evidence for routine recommendation in long-term-catheterised adults.
Safety
Cranberry is generally well tolerated at typical food-supplement doses. Principal practical considerations: drink adequate water; flag use to anticoagulation team if on warfarin; pregnant women with UTI symptoms need prompt clinical care, not self-treatment.
Talk to your pharmacist or GP first if you:
- You take warfarin — flag use to your anticoagulation team.
- You are pregnant or breastfeeding — talk to your midwife about UTI symptoms first.
- You have a history of kidney stones — concentrated cranberry supplements may modestly raise oxalate excretion; clinical relevance limited but worth discussing.
- You have UTI red flags — fever, flank pain, blood in urine, vomiting, pregnancy — see GP / NHS 111 / Pharmacy First. Cranberry is not acute-UTI treatment.
- Recurrent UTIs persist on cranberry — discuss prescribed prophylaxis options with your GP.
Common side effects: GI symptoms — mild nausea or loose stools at higher doses. Rare allergic reactions.
Pregnancy and breastfeeding
UTI in pregnancy needs prompt clinical care. Cochrane evidence in pregnancy not consistently positive. Talk to your midwife.
Limited data; talk to your pharmacist or GP.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Known cranberry / Ericaceae allergy.
- Active acute UTI requiring antibiotic care.
Drug interactions
- Warfarin — historical case-report concern; subsequent prospective trials largely null. Disclose use to anticoagulation team.
- PPIs / gastric acid suppressants — minor; may modestly affect PAC stability.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Mild GI symptoms — nausea, diarrhoea, loose stools at high intake.
Rare side effects
- Allergic reactions in cranberry-allergic individuals.
- Theoretical kidney-stone risk (oxalate) at very high chronic intake — clinical relevance limited.
How to take it
- Typical supplemental range
- Trial-grade dose: ≥36 mg PACs/day (BL-DMAC method). One concentrated extract tablet typically delivers cranberry equivalent of 5,000–7,500 mg whole fruit and may declare 36–72 mg PACs. Lower-strength capsules and juice products may need multiple servings to reach the trial dose.
- Timing
- No specific timing requirement. Many users take with breakfast or with the largest meal of the day.
How to spot quality
Look for
- PAC content declared in milligrams per serving — ideally measured by the BL-DMAC standardised assay.
- Vaccinium macrocarpon named (American cranberry — the species in trials).
- Extract ratio declared if used (10:1, 36:1, etc.).
- Sugar content low or absent — added sugars dilute the value of the supplement.
- GMP-certified manufacture.
Red flags
- Cranberry mg only, no PAC content.
- Sweetened cranberry juice cocktail labelled as a UTI supplement.
- Marketing implies acute UTI treatment.
- Marketing implies the product kills bacteria (it does not).
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
D-Mannose
Limited evidenceCranberry proanthocyanidins and D-mannose both interfere with E. coli adhesion to the bladder wall — different mechanisms, same target.
Most uncomplicated UTIs are caused by uropathogenic Escherichia coli that attach to the bladder urothelium via FimH adhesins on type-1 pili. D-mannose is a simple sugar that binds the FimH adhesin competitively, occupying the binding site that would otherwise attach to mannose-like residues on bladder epithelial cells. Cranberry contains A-type proanthocyanidins (PACs) that interfere with P-fimbriae adhesion through a separate mechanism. Combination supplementation is rationalised by attacking both adhesin systems; the strongest individual-component evidence is for D-mannose. Neither replaces antibiotic treatment of acute infection.
Evidence: Kranjčec 2014 (World J Urol 32:79) randomised 308 women with recurrent UTI to 2 g D-mannose powder daily, 50 mg nitrofurantoin daily, or no prophylaxis for 6 months. UTI recurrence: 14.6% (D-mannose), 20.4% (nitrofurantoin), 60.8% (no prophylaxis); D-mannose was non-inferior to nitrofurantoin and significantly better than no prophylaxis (p<0.0001). Cranberry trials (multiple) are heterogeneous and have produced mixed results; the most-recent Cochrane update found a modest reduction in recurrent UTI in women. Direct head-to-head or combination trials are sparse. [5]
Doses studied: Kranjčec D-mannose dose: 2 g powder dissolved in 200 ml water once daily for prophylaxis. Cranberry: typical 36 mg PAC standardised extract daily. Acute UTI: see GP — supplementation does not replace antibiotic treatment.